Advancements in clinical developments in neo/adjuvant drug therapy for resectable melanoma: ASCO Annual Congress – June 2022
Open Access
- 17 May 2023
- journal article
- research article
- Published by Rossijskoe Obschestvo Dermatovenerologov i Kosmetologov in Vestnik dermatologii i venerologii
- Vol. 99 (2) , 10-17
Abstract
In the structure of the incidence of skin tumors, melanoma accounts for a relatively smaller percentage, but that disease is associated with higher risk of an adverse outcome compared with many other malignancies. The study of innovative clinical developments in drug therapy for resectable melanoma, presented at the American Society of Clinical Oncology Annual Meeting June 2022. The best clinical developments in drug treatment of patients with resectable melanoma were selected for analysis: 1) phase 3 study KEYNOTE-716; 2) PRADO; 3) Neo Trio; 4) SWOG 1512. The presented developments bring extremely promising results for melanoma therapy workflows. The use of cutting-edge anti-cancer therapeutics acting on various molecular targets drastically improves the tumor response as well as straitens the appearance of treatment-related adverse events.Keywords
This publication has 12 references indexed in Scilit:
- Distant metastasis-free survival with pembrolizumab versus placebo as adjuvant therapy in stage IIB or IIC melanoma: The phase 3 KEYNOTE-716 study.Journal of Clinical Oncology, 2022
- Neoadjuvant PD-1 blockade in patients with resectable desmoplastic melanoma (SWOG 1512).Journal of Clinical Oncology, 2022
- NeoTrio: Randomized trial of neoadjuvant (NAT) pembrolizumab (Pembro) alone, in sequence (SEQ) with, or concurrent (CON) with dabrafenib plus trametinib (D+T) in resectable BRAF-mutant stage III melanoma to determine optimal combination of therapy.Journal of Clinical Oncology, 2022
- The Role of Treatment Sequencing with Immune-Checkpoint Inhibitors and BRAF/MEK Inhibitors for Response and Survival of Patients with BRAFV600-Mutant Metastatic Melanoma—A Retrospective, Real-World Cohort StudyCancers, 2022
- Skin cancer: Primary, secondary, and tertiary prevention. Part IJournal of the American Academy of Dermatology, 2022
- Immune Response Checkpoint Inhibitors: New Risks of a New Class of Antitumor AgentsSafety and Risk of Pharmacotherapy, 2020
- Epidemiology of skin melanoma in the Russian Federation and in the city of Moscow for 10 years (2008—2018)Russian Journal of Clinical Dermatology and Venereology, 2020
- Multidisciplinary treatment strategies in high-risk resectable melanoma: Role of adjuvant and neoadjuvant therapyCancer Treatment Reviews, 2018
- High response rate to PD-1 blockade in desmoplastic melanomasNature, 2018
- A systematic review of worldwide incidence of nonmelanoma skin cancerBritish Journal of Dermatology, 2012